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Abstract
Dimorfolido-N-trichloroacetylphosphorylamide (HL1) and dimorfolido-N-benzoylphosphorylamide (HL2) as
representatives of carbacylamidophosphates were synthesized and identified by the methods of IR, 1H, and 31P
NMR spectroscopy. In vitro HL1 and HL2 at 1 mM concentration caused cell specific and time-dependent decrease
of leukemic cell viability. Compounds caused the similar gradual decrease of Jurkat cells viability at 72 h (by 35%).
HL1 had earlier and more profound toxic effect as compared to HL2 regardless on leukemic cell line. Viability of
Molt-16 and CCRF-CEM cells under the action of HL1 was decreased at 24 h (by 32 and 45%, respectively) with no
substantial further reducing up to 72 h. Toxic effect of HL2 was detected only at 72 h of incubation of Jurkat and
Molt-16 cells (cell viability was decreased by 40 and 45%, respectively).
It was shown that C60 fullerene enhanced the toxic effect of HL2 on leukemic cells. Viability of Jurkat and CCRF-
CEM cells at combined action of C60 fullerene and HL2 was decreased at 72 h (by 20 and 24%, respectively) in
comparison with the effect of HL2 taken separately.
In silico study showed that HL1 and HL2 can interact with DNA and form complexes with DNA both separately and
in combination with C60 fullerene. More stable complexes are formed when DNA interacts with HL1 or C60 + HL2
structure. Strong stacking interactions can be formed between HL2 and C60 fullerene. Differences in the types of
identified bonds and ways of binding can determine distinction in cytotoxic effects of studied compounds.
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Background
Nowadays, it is important to create new biocompatible
nanomaterials that exhibit pharmacological properties,
antitumor activity, and modulate the biological effects of
chemotherapeutic drugs.
Carbacylamidophosphates as the structural analog of
β-diketones, that are promising class of biologically ac-
tive compounds with antimitotic and antiproliferative
activities, can be used as antitumor agents [1–3].
In previous study with the use of in silico analysis, we
have shown that dimethyl-N-(benzoyl)amidophosphate
as representative of carbacylamidophosphates possesses
an antitumor activity and interacts with DNA [4, 5].
In vitro toxic effects (decrease of cell viability and in-
crease of ROS production) of 2.5 mM dimethyl-N-(ben-
zoyl)amidophosphate on leukemic L1210 cells were
demonstrated. It was shown that toxic effects of di-
methyl-N-(benzoyl)amidophosphate on leukemic cells
could be facilitated by C60 fullerene [5].
C60 fullerene is a chemically stable carbon nanostruc-
ture, able to interact with biomolecules and penetrate
through plasma membrane inside the cell [6–8] and,
thus, it can be used in biomedical applications [9–13].
C60 fullerene can form complexes with chemotherapeu-
tic drugs such as doxorubicin, cisplatin, and paclitaxel,
reducing their cytotoxic effect and enhancing the thera-
peutic effect [14–18].
Two carbacylamidophosphate derivatives with differ-
ent substituents were used in this study: dimorfolido-
N-trichloroacetylphosphorylamide (HL1) contained
CCl3 group (Fig. 1a) and dimorfolido-N-benzoylpho-
sphorylamide (HL2)—benzene ring (Fig. 1b) at car-
bamide group.
The aim was to study the leukemic cell viability under
the action of HL1 and HL2 separately and in combin-
ation with C60 fullerene and to estimate their interaction




lium bromide], DMSO (Sigma-Aldrich Co, Ltd, USA).
Characterization of Chemical Compounds
HL1 and HL2 were synthesized at the Department of
Inorganic Chemistry, Chemical Faculty of Taras
Shevchenko National University of Kyiv according to
methods described earlier [19]. The composition of
the synthesized compounds was confirmed by NMR
and IR spectroscopy and measuring the melting
points. The purity of above compounds was ≥98%.
IR measurements were performed on a UR-10 and
a Perkin–Elmer Spectrum BX spectrometer on sam-
ples as KBr pellets. 1H and 31P NMR spectra in
DMSO-d6 and methanol-d4 solutions were obtained
on a Varian 400 NMR spectrometer at room
temperature. Chemical shifts are referenced to SiMe4
as interior standard for 1H NMR and H3PO4 as exter-
ior standard for 31P NMR.
HL1: m. p. 205 °C; IR (KBr, cm–1): ν = 3013 (NH),
1728 (CO), 1201 (PO); 1H NMR (DMSO-d6): 3.61 (m,
8H, CH2λ), 3.17 (m, 8H, CH2β).
HL2: m. p. 178 °C; (KBr, cm–1): ν = 3100 (NH),
1685 (CO), 1200 (PO); 1H NMR (methanol-d4): 3.36
(m, 8H, CH2λ), 3.24 (m, 8H, CH2β), 7.49, 7.56, 7.90
(m, C6H5) (8:8:5:1).
The synthesized compounds were dissolved in 10%
DMSO to a final concentration of 0.05 M.
Characterization of C60 Fullerene Aqueous Solution
A highly stable aqueous colloid solution of C60 fullerene
(10−4 M, purity >99.5%, nanoparticle average size up to
50 nm) was synthesized in Technical University of
Ilmenau (Germany) as described in [20, 21].
In Vitro Study
Cell Culture
The experiments were done on different human acute
T cell leukemic cell lines. Cell lines were purchased
from the Leibniz Institute DSMZ-German Collection
of Microorganisms and Cell Cultures: Jurkat (ACC
282), CCRF-CM (ACC 240), and Molt-16 (ACC 29).
The cells were cultured in RPMI 1640 medium sup-
plemented with 10% FBS, 1% penicillin/streptomycin,
and 2 mM gluthamine using 25-cm2 flasks at 37 °C
with 5% CO2 in humidified incubator.
a b
Fig. 1 Carbacylamidophosphates. a Dimorfolido-N-trichloroacetylphosphorylamide (HL1). b Dimorfolido-N-benzoylphosphorylamide (HL2)
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Cells in RPMI 1640 medium were preincubated with
C60 fullerene (10
−5 M) during 1 h. After that, HL1 or
HL2 was added to above medium and incubated for 24,
48, and 72 h.
Cell survival without addition of chemical compounds
and C60 fullerene was received as 100% (control sample
contained 0.05 M DMSO).
Cell Viability (MTT) Assay
Cell viability was assessed by the MTT reduction
assay [22]. At indicated time points of incubation,
200 μl aliquots (1 × 105 cells) was placed into the 96-
well microplates, 20 μl of MTT solution (4 mg/ml)
was added to each well, and the plates were incu-
bated for another 2 h. The culture medium was then
replaced with 100 μl of DMSO; diformazan formation
was determined by measuring absorption at 570 nm
with a microplate reader Tecan Infinite M200 Pro
(Switzerland).
In Silico Study
The double-helix DNA molecule was used as a template
from PDB (Protein Data Bank) base. The interactions of
DNA molecule with HL1 or HL2 separately and in com-
bination with C60 fullerene have been studied. We took
into consideration the following structures of DNA mol-
ecule: 2MIW (CCATCGCTACC—intercalation of com-
pound into a small groove of DNA helix), 1XRW
(CCTCGTCC—intercalation of compound into a small
groove of DNA helix), and 2M2C (GCGCATGC-
TACGCG—binding of compound with large and small
grooves of DNA helix). We applied the algorithm of
systematical docking (SDOCK+), built-in the QXP
package (this method demonstrates all possible con-
formations of the studied structures with the minimal
value of root mean square deviation (Rmsd)) [23]. To
each compound (HL1 or HL2) in combination with
the C60 fullerene, we generated 300 potentially pos-
sible complexes with DNA, the 10 best of which were
selected for the next stage, using a scoring function,
built-in the QXP package [24].
The interactions of the DNA molecule with HL1 or
HL2 separately and in combination with the C60 fuller-
ene were characterized by the following parameters: (1)
the number of hydrogen bonds, (2) the area of contact-
ing surfaces of DNA and corresponding structure, (3)
the distance between the DNA and docked structure,
and (4) the total energy of the binding structure.
To assess the stability of the complexes of chemical
compounds with C60 fullerene, we conducted the short-
molecular dynamics (MD, 25 ps) using a Nosé-Poincaré-
Anderson algorithm (NPA) [25, 26]. The calculations
were performed on the following parameters:
temperature (in K)—300; pressure (in kPa)—100;
binding involving the hydrogen atom or ligand was lim-
ited by the algorithm [26].
Statistical Analysis
The data were represented as M ± SD of more than
five independent experiments. Mean (M) and standard
deviation (SD) were calculated for each group. Statis-
tical analysis was performed using two-way ANOVA
followed by post Bonferroni’s tests. A value of p < 0.05
was considered statistically significant. Data process-
ing and plotting were performed by IBM PC using
specialized applications GraphPad Prism 7 (GraphPad
Software Inc., USA).
Results and Discussion
In the structures of HL1 and HL2, the carbonyl and
phosphoryl groups are in anti-positions to each other
as in most carbacylamidophosphates. In the structure
of HL1, the bond lengths C–O (1.202(4) A) and C–N
(1.346(4) A) are influenced by the substituent nature
near the carbonyl group and have typical values for
trichloracetylamide derivatives. The carbon atom of
CCl3 group has a tetrahedral environment (Fig. 1a).
For HL2, the planar benzene ring is rotated relative
to the plane of the carbamide group on angle
22.34(27)°, which does not exclude the possibility of
π-interaction between the benzene ring and the
(O)CNP(O) fragment (Fig. 1b). It should be noted a
close contact between the electrophilic phosphorus
and nucleophilic oxygen atoms of the carbonylic
group for both ligands. The distance between above-
mentioned atoms 3.02 A for HL1 and 3.122(3) A for
HL2 is slightly below than the sum of the Van der
Waals radii of phosphorus and oxygen atoms (3.3 A)
that can be considered as an evidence of estimate co-
valent contribution in interatomic interaction [27, 28].
More electronegative character of CCl3 group in com-
parison with C6H5 (phenyl) group reflects in the short-
ening of intramolecular hydrogen bonds N···O and O…H
type: for HL1—1.81(1) A and 2.73(1) A, and for
HL2—2.103(3) A and 2.946(3) A, respectively.
HL1 and HL2 at 1 mM concentration were screened
for their toxicity against human T cell leukemic cells
Jurkat, CCRF-CEM, and Molt-16 using MTT assay.
It was shown that HL1 and HL2 decrease the viability
of leukemic cells. The observed toxic effect was cell spe-
cific and time dependent (Fig. 2).
HL1 and HL2 caused the similar gradual decrease of
Jurkat cells viability by about 35% at 72 h (Fig. 2a).
The dynamics of Molt-16 and CCRF-CEM cell death
under the action of HL1 was similar: cell viability was
decreased at 24 h with no substantial further reducing
up to 72 h. But the value of toxic effect was higher on
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CCRF-CEM cells (52% at 72 h) as compared with Molt-
16 cells (37% at 72 h) (Fig. 2b, c).
Toxic effect of HL2 against Molt-16 cells was less pro-
nounced as compared with HL1. Molt-16 cells viability
was decreased (by 45%) only in 72 h, while no substan-
tial decrease of CCRF-CEM cell viability was detected
(Fig. 2b, c).
The obtained data enabled us to conclude that HL1
had earlier and more profound toxic effect as compared
to HL2 regardless of leukemic cell lines. Toxic effect of
HL2 was detected only at 72 h of incubation of Jurkat
and Molt-16 cells (Fig. 2a, b).
The higher HL1 toxic effect could be connected with
the presence in its structure of Cl atoms, which possess
alkylating potential and are the constituents of chemo-
therapeutic drug such as cisplatin [29].
The high tumor-specific toxicity of β-diketones deriva-
tives was confirmed by evaluating their effects against
human carcinoma cell lines HSC-3 (oral squamous),
HSG (submandibular gland), and HL-60 (promyelocytic
leukemia) as well [1].
It was shown that β-diketones exist mainly in the
enolic form and form metal chelates with Fe, Cu, and
Zn ions. Recent studies suggest that metal chelates
induce apoptotic cell death in various tumor cell lines
and they are potential antitumor agents against malig-
nant melanomas [30, 31].
To estimate the possibility to enhance the toxicity of
studied compounds, their combined action with C60 ful-
lerene on leukemic cells was investigated.
It was shown that C60 fullerene (10
-5 M) does not
affect the viability of leukemic cells during incubation
period (data not shown).
No increase of HL1 toxicity was detected when Jurkat,
Molt-16, or CCRF-CEM cells were preincubated with
C60 fullerene (data not shown).
At combined action of C60 fullerene and HL2, an
enhanced toxic effect in comparison with the effect of
HL2 taken separately was observed. In this case, a
viability of Jurkat and CCRF-CEM cells was addition-
ally decreased by 20 and 24% at 72 h, respectively
(Fig. 3).
At the same time, no enhancement of HL2 toxic effect
under the combined action with C60 fullerene against
Molt-16 cells was found (Fig. 3).
In vitro experiments combined with modeling
simulation have shown that C60 fullerene is signifi-
cantly accumulated in human leukemic K562 cells
a b
c
Fig. 2 Viability of leukemic cells in the presence of 1 mM HL1 or HL2. M ±m, n = 8; *p < 0.05 compared to control cells. a Jurkat cells. b Molt-16
cells. c CCRF-CEM cells
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since it could not be efficiently effluxed by P-gp pro-
tein [32]. So, C60-induced enhancement of HL2 cyto-
toxicity could be triggered by C60 fullerene
intracellular interactions at the level of membrane
phospholipids, cytosolic proteins, DNA, and other
biological structures. It is well known that nanoparti-
cles can interact with organic molecules using van
der Waals forces, hydrophobicity, π-interactions, and
enthalpy driven [33]. Previously with the use of
molecular modeling, we have shown that stable C60-
DNA complex is formed after C60 fullerene binding
with DNA [5].
Computer simulation of HL1 and HL2 interactions
with DNA was used to estimate the possible nature of
their bonds with biological molecules and the ability of
C60 fullerene to modify such interactions.
It was shown that HL1 forms the stable complexes
with DNA when bound with a large groove and dur-
ing the intercalation into a small groove. So, when
the binding shift of DNA double helix was 3.07 Å,
and for HL1, it equals to 1.8 Å; at intercalation, the
DNA molecule shifted to 3.24 Å, and HL1—2.24 Å
(Fig. 4).
According to energy parameters, the formed com-
plexes are not rigid (Table. 1). So, when binding HL1
with a large groove, the contact energy is −34.8 kJ/mol,
and at intercalation into DNA, it is −61.0 kJ/mol; the
steric clashes between DNA and HL1 in these cases are
1.4 and 7.7 kJ/mol, respectively.
It is shown that HL2 forms the stable complexes
with DNA only when bound with a small groove
(Fig. 5a). The shift of DNA is 2.09 Å, and for
HL2—1.45 Å.
When binding HL1 as well as HL2, observe no
changes in their nucleotide environment (only insignifi-
cant movements in space take place).
The interaction of the DNA molecule with HL1 or
HL2 in combination with C60 fullerene was studied
depending on the sequence of interactions. If initially
C60 fullerene binds with DNA, and then HL1 or HL2,
the formed structure is designated as C60 + HL1 or
C60 + HL2; otherwise—HL1 + C60 or HL2 + C60. We
Fig. 3 Viability of leukemic cells at the combined action of 1 мM HL2 and C60 fullerene. M ±m, n = 8; *p < 0.05 compared to control cells; #p <
0.05 compared to HL2
Fig. 4 The interaction of DNA molecule with HL1: a and b—binding with small and large grooves; c—intercalation into a small groove. The used
DNA structures of the PDB database: a and b—2M2C; c—1XRW
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considered two options of the binding-studied struc-
tures with DNA molecule, namely with small and
large grooves, and also the possible intercalation of
these structures into the small groove (Figs. 6 and 7).
The calculated energy parameters of the interaction
of these structures with DNA molecule are given in
Table 1.
HL1 + C60 or C60 + HL1: at binding HL1 + C60 struc-
ture with small and large grooves of DNA, there is a
significant shift of the C60 fullerene compared to HL1
compound: Rmsd value is 5.22 Å in a small groove, and
in a large groove—8.08 Å; meanwhile, Rmsd value for
HL1 is 2.92 and 2.93 Å in small and large grooves, re-
spectively (Fig. 6a, b).
At intercalation of the studied structures into a
small groove of the DNA molecule, the significant
values of Rmsd for C60 fullerene in the cases of HL1
+ C60 (5.72 Å) and C60 + HL1 (6.42 Å) are also ob-
served. Due to such shift of C60 molecule, a partial
displacement of HL1 compound (Rmsd value is
1.99 Å) from the intercalation site (Fig. 6c) takes
place. In the case of C60 + HL1, a similar effect is ob-
served for C60 molecule (Rmsd value for HMF com-
pound is 2.69 Å) (Fig. 6d).
HL2 + C60 or C60 + HL2: in these cases, there is a sig-
nificant shift of the C60 fullerene with respect to the
HL2 compound at their combined interaction with DNA
in small and large grooves (Fig. 7a, b). So, Rmsd value
for C60 fullerene in a small groove is 7.16 Å (for
HL2—1.69 Å), and in a large groove—8.56 Å (for
HL2—3.85 Å). However, a complete break of stacking
interaction between C60 fullerene and HL2 does not
happen.
At intercalation of the studied structures into a small
groove of DNA, the C60 fullerene forms the strong
stacking interactions with HL2 and nitrogenous bases of
DNA double helix (Fig. 7c, d). So, after molecular dock-
ing, its shift is negligible: in the case of HL2 + C60, the
Rmsd value for C60 fullerene is 3.99 Å (for HL2—1.36 Å),
and in the case of C60 + HL2—2.7 Å (for HL2—3.29 Å).
In addition, at such intercalation, there is no displace-
ment of chemical compound from the original nucleo-
tide environment.
As shown in Table 1, the energy parameters of C60 +
HL1 or C60 + HL2 intercalation into DNA molecule are
lower for C60 + HL1 structure than for HL1 + C60 or
HL2 + C60 structures. The Bump value for C60 + HL1
structure is 17.1 kJ/mol and Int—4.2 kJ/mol, while for
Table 1 The energy parameters (in kJ/mol) of interaction of the
studied structures with DNA double helix
Structure The energy parameters
FreE Cntc Hbnd Bump Int
The binding with a large groove
HL1 −1.8 −34.8 −0.4 1.4 4.0
HL2 −3.6 −41.7 −1.8 1.6 3.7
HL1 + C60 −20.3 −70.5 −1.1 7.8 3.1
HL2 + C60 −20.3 −66.8 0.0 6.5 3.9
The binding with a small groove
HL1 −4.9 −49.0 −2.7 3.9 4.8
HL2 −4.7 −61.1 0.0 11.2 7.2
HL1 + C60 −24.0 −87.8 0.0 11.2 5.3
HL2 + C60 −31.1 −84.3 −0.8 6.3 3.8
The intercalation into a small groove
HL1 −7.0 −61.0 −1.7 7.7 6.8
HL2 2.3 −63.0 0.0 12.6 10.4
HL1 + C60 −22.5 −107.0 −1.4 19.6 7.2
C60 + HL1 −22.8 −97.1 0.0 17.1 4.2
HL2 + C60 −21.8 −100.0 0.0 18.6 5.1
C60 + HL2 −26.5 −89.9 −2.4 12.7 4.2
FreE the total energy of binding DNA and related structure, Cntc the contact
energy of interacting compounds (the related structure with DNA), Hbnd the
energy of hydrogen interactions, Bump the energy of steric clashes between
DNA and build-in structure, Int the energy of steric clashes between the atoms
of build-in structure
Fig. 5 The interaction of DNA molecule with HL2: a and b—binding with small and large grooves; c—intercalation into a small groove. The used
DNA structures of the PDB database: a and b—2M2C; c—1XRW
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HL1 + C60 structure, these parameters are higher—19.6
and 7.2 kJ/mol, respectively. These data allow to suggest
that the studied chemical compounds form more stable
structures with C60 fullerene when C60 molecule is ini-
tially bound to DNA.
Taking into account the structural features of the stud-
ied compounds and C60 fullerene, one can suggest the
formation of cation-π bonds between HL1 and C60 ful-
lerene due to CCl3 group (Fig. 6a) and stacking interac-
tions between HL2 and C60 fullerene mediated by the
presence of benzene ring (Fig. 7a).
Thus, using the computer modeling, it was found that
HL2 and HL1 compounds in combination with C60 ful-
lerene are potentially capable of binding to DNA
molecule.
Conclusions
We have estimated effect of two carbacylamidopho-
sphate derivatives with different substituents on the
viability of leukemic cells of three lines. Dimorfolido-
N-trichloroacetylphosphorylamide (HL1) and dimor-
folido-N-benzoylphosphorylamide (HL2) at 1 mM
concentration in the cellular medium caused the de-
crease of cell viability, which value was dependent
on the cell type and duration of incubation. HL1 and
HL2 caused the similar gradual decrease of Jurkat
cells viability. HL1 had earlier and more profound
toxic effect as compared to HL2 both on Molt-16
and CCRF-CEM cells. Toxic effect of HL2 was de-
tected only at 72 h of Jurkat and Molt-16 cells
incubation.
It was shown that C60 fullerene facilitated the toxic ef-
fect of HL2 on Jurkat and CCRF-CEM cells at 48 and
72 h.
By use of computer simulation, the interactions of
DNA molecule with HL1 or HL2 separately and in
combination with C60 fullerene were studied. The
chemical compounds formed the stable complexes
with DNA: HL1 when binding with a great groove
and at intercalation into a small groove, while HL2
only when bound with a small groove. At the com-
bined action of HL1 or HL2 with C60 fullerene, the
C60 + HL2 structure formed the stable complex with
DNA when bound with a small groove and at inter-
calation into it, while the C60 + HL1 structure formed
the stable complex with DNA only in one case—when
binding with a large groove. In this case, the strong
stacking or cation-π interactions can be formed be-
tween these chemicals and C60 fullerene. Thus, the
chemical compounds form the stable complexes with
DNA both individually and in combination with C60
fullerene, but the differences in the types of bonds
and ways of binding could be the cause of their dif-
ferent cytotoxic effects.
Fig. 6 The interaction of DNA molecule with HL1in combination with the C60 fullerene (HL1 + C60 or C60 + HL1): a and b—binding with small
and large grooves and c and d—intercalation into a small groove. The used DNA structures of the PDB database: a and b—2M2C; c—1XRW;
and d—2MIW
Fig. 7 The interaction of DNA molecule with HL2 in combination with C60 fullerene (HL2 + C60 or C60 + HL2): a and b—binding with small and
large grooves and c and d—intercalation into a small groove. The used DNA structures of the PDB database: a and b—2M2C; c—1XRW;
and d—2MIW
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